KALV
Kalvista Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.43B
P/E Ratio
—
EPS
$-3.94
Beta
-0.12
52W High
$26.85
52W Low
$9.83
50-Day MA
$21.67
200-Day MA
$16.00
Dividend Yield
—
Profit Margin
-118.70%
Forward P/E
25.25
PEG Ratio
0.00
About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops, and markets small-molecule protease inhibitors for illnesses with unmet needs. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $114.48M |
| Gross Profit (TTM) | $58.47M |
| EBITDA | $-138.45M |
| Operating Margin | -57.40% |
| Return on Equity | -190.20% |
| Return on Assets | -61.00% |
| Revenue/Share (TTM) | $2.11 |
| Book Value | $-0.05 |
| Price-to-Book | 49.03 |
| Price-to-Sales (TTM) | 12.46 |
| EV/Revenue | 906.22 |
| EV/EBITDA | -3.53 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 30.70% |
| Shares Outstanding | $53.24M |
| Float | $38.21M |
| % Insiders | 1.66% |
| % Institutions | 131.32% |
Historical Volatility
HV 10-Day
2.20%
HV 20-Day
116.55%
HV 30-Day
101.72%
HV 60-Day
85.52%
HV Rank
93.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($28.60 target)
3
Buy4
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026